At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Androgen Deprivation and Localized Radiotherapy to Metastases in Patients With Oligometastatic Hormone - Sensitive Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Bicalutamide, Goserelin Acetate, and 3 other interventions for PSA Level Greater Than Two and Stage IV Prostate Adenocarcinoma AJCC v7. Active but no longer recruiting, targeting 29 participants across 2 sites.
Detailed Summary
This phase II trial studies how well hormone therapy and intensity-modulated radiation therapy work in treating patients with prostate cancer that has spread to other places in the body. Androgens can cause the growth of prostate cancer cells. Anti-hormone therapy using goserelin, leuprolide acetate, or bicalutamide, may lessen the amount of androgens made by the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving hormone therapy and intensity-modulated radiation therapy may work better in treating patients with prostate cancer.
Study Details
Timeline
Interventions
Given PO
Given SC
Undergo IMRT
Correlative studies
Given via injection